
BBOT
Healthcare · Biotechnology · $171.7M market cap
$2.14-0.21 (-8.9%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -18.0% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2026 | After the close | -0.65 | -0.43 | +33.8% |
| Aug 11, 2026 | After the close | -0.55 | -0.71 | -29.1% |
| May 13, 2026 | Time not confirmed | -0.51 | -526.11 | -102777.3% |
| Mar 5, 2026 | After the close | -0.66 | -0.49 | +25.8% |
| Nov 12, 2025 | After the close | -0.34 | -1.03 | -202.9% |
| Sep 3, 2025 | Time not confirmed | — | -50.33 | — |
| May 28, 2025 | Time not confirmed | — | -50.13 | — |
| Mar 11, 2025 | Time not confirmed | — | 0.08 | — |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C…